Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
Data ReadoutpositiveIvonescimabPembrolizumabPositive
AI Analysis
Summary
AstraZeneca's ivonescimab demonstrated positive overall survival results versus pembrolizumab in the HARMONi-2 Phase 3 trial for first-line PD-L1-positive NSCLC, with data presented at WCLC 2026.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Positive overall survival results from HARMONi-2 trial
Importance:8/10
Sentiment:
0.80
NSCLConcologyimmunotherapyPD-L1Phase 3clinical trialWCLC 2026overall survival
Related Companies
Read the original article
Published by yahoo_finance on September 13, 2026 6:59 AM